Singular Genomics Systems Profit Margin

The latest profit margin for OMIC is -3237.88% as of September 2024. That compares with -3513.91% in the prior-year period — up 7.9% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Singular Genomics Systems's historical trend and sector peers before judging valuation or financial health.

Over the past year, OMIC's profit margin moved from -3513.91% to -3237.88% — a 7.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Singular Genomics Systems's valuation or profitability profile.

Against Healthcare companies, OMIC currently prints -3237.88% for profit margin, while the sector average sits near 21.34%. That is roughly 15276.3% below the sector mean. Large gaps often invite a closer look at Singular Genomics Systems's growth, margins, and balance sheet.

Profit Margin shows how effectively Singular Genomics Systems converts resources into returns. At -3237.88%, OMIC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -3513.91% in the prior-year period — up 7.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting OMIC's profit margin (-3237.88%), review year-over-year change from -3513.91%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.